Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-03-27
2007-03-27
Wilson, James O. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S224000, C544S336000, C540S450000, C540S484000, C514S218000
Reexamination Certificate
active
10343171
ABSTRACT:
The invention concerns novel cdc25 phosphatase inhibitors, and in particular cdc25-C, which correspond to the general formula (I) wherein: A represents a carbocyclic aryl radical optionally substituted 1 to 3 times by one or more radicals independently selected among a halogen atom and an alkyl, hydroxy, alkoxy, alkylthio or NR1R2radical wherein R1and R2represent a hydrogen atom or an alkyl radical or R1and R2form together with the nitrogen atom a heterocycle of 4 to 7 members comprising 1 to 2 heteroatoms, the members required to complete the heterocycle being selected independently among the CR3R4—, —O—, —S and NR5-radicals, R3and R4representing independently each time they are involved a hydrogen atom or an alkyl, hydroxy, alkoxy, amino, alkylamino or dialkylamino radical, and R5representing independently each time it is involved a hydrogen atom or an alkyl radical, or A represents a phenyl radical substituted by a phenyl radical optionally substituted 1 to 3 times by one or more radicals selected independently among a halogen atom and an alkyl, hydroxy, alkoxy, alkylthio or NR1R2radical wherein R1and R2represent a hydrogen atom or an alkyl radical; B represents a —(CH2)i—(CO)— or —NH—CO—(CH2)nor —(CH2)pand i and n being integers from 0 to 2 and p being an integer from 0 to 1; W represents a hydrogen atom or an alkyl radical; X represents a —(CH2)q— or (CH2)j—CO—(CH2)r—, q being an integer from 1 to 4 and j and r being integers from 0 to 6; Y represents in particular a nitrophenyl, aminophenyl, alkylaminophenyl or dialkylaminophenyl radical or the radical (T)
REFERENCES:
patent: 4032635 (1977-06-01), Umezawa et al.
patent: 9505363 (1995-02-01), None
patent: 9842696 (1998-10-01), None
patent: 0017190 (2000-03-01), None
Lis et al. “Synthesis of Novel Aryloxy- Propanolamines . . . ”, Journal of Medicinal Chemistry, (1990), 33 (10), 2883-91.
Bourhim et al, “Design . . . Retrobenzamides”, Arzneim.-Forsch. (1999), 49(2), 81-87, XP000992843.
Yamagami et al, “A Quantitative . . . Phenylacetanilides”, Hem. Pharm. Bull., vol. 32, No. 12, 1984, pp. 5003-5009, XP002166155.
Database Chemabs en ligne! Chemical Abstracts Service, Columbus, Ohio, US: Fujisawa Pharmaceutical Co., Ltd., Japan: Preparation of biphenyl compounds as drugs: retrieved from STN Database accession No. 115; 114130 XP002166157.
“The Merck Index”1996, Merck & Co., Inc. XP002166156, Niclosamide p. 1118.
Database Chemabs ‘en’ligne! Chemical Abstracts Service, Columbus, Ohio, US: Umezawa Hamao et al: “Benzanilide Derviatives” retrieved from STN Database accession No. 87:5662 XP002166158.
Coburn et al, “Potential . . . Viscosus” J. Med. Chem., vol. 24, 1981 pp. 1245-1249, Jan. 28, 2003.
Brezak Pannetier Marie-Christine
Ducommun Bernard
Galcera Contour Marie-Odile
Goubin Gramatica Françoise
Lanco Christophe
Muserlian Charles A.
Societe de Conseils de Recherches et d'Applications Scientifique
LandOfFree
Cdc25 phosphatase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cdc25 phosphatase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cdc25 phosphatase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3798045